The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
we know that with these amyloid drugs that remove amyloid we often will see changes in mri either edema or swelling or microhemorrhages so arya e for edema aria h for hemorrhages often asymptomatic but certainly were very significant in some of the earlier iterations of anti-amyloid drugs and drug trials that were going on and there was a distinct difference between the risk of arya and e4 carriers versus not
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
yeah there was a protocol amendment they did amend the protocol for e4 to go to 10 migs per gig
often asymptomatic but certainly um were very significant in some of the earlier iterations of anti-amyloid drugs and drug trials that were going on
and there was a distinct difference between the risk of arya and e4 carriers versus not
one of the reasons that they give the apo e4 carriers a lower dose is because of the risk of arya or amyloid related imaging abnormalities so we know that with these amyloid drugs that remove amyloid we often will see changes in mri either edema or swelling or microhemorrhages